-
Something wrong with this record ?
Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak
S. Zakharov, D. Pelclova, T. Navratil, J. Belacek, M. Komarc, M. Eddleston, KE. Hovda,
Language English Country England, Great Britain
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Antidotes administration & dosage adverse effects therapeutic use MeSH
- Time Factors MeSH
- Length of Stay MeSH
- Adult MeSH
- Disease Outbreaks * MeSH
- Ethanol administration & dosage adverse effects therapeutic use MeSH
- Risk Assessment MeSH
- Hospitalization MeSH
- Administration, Intravenous MeSH
- Intensive Care Units MeSH
- Middle Aged MeSH
- Humans MeSH
- Linear Models MeSH
- Logistic Models MeSH
- Methanol poisoning MeSH
- Adolescent MeSH
- Young Adult MeSH
- Multivariate Analysis MeSH
- Poisoning diagnosis drug therapy mortality MeSH
- Cross-Sectional Studies MeSH
- Pyrazoles administration & dosage adverse effects therapeutic use MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Chi-Square Distribution MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Geographicals
- Czech Republic MeSH
CONTEXT: Mass or cluster methanol poisonings are frequently reported from around the world. The comparative effectiveness of ethanol and fomepizole as antidotes for methanol poisoning is unknown due to the difficulty of performing a randomized controlled trial. OBJECTIVE: During an outbreak of mass poisonings in the Czech Republic in 2012-2014, we compared the effects of antidotes on the frequency of health sequelae and mortality. METHODS: The study was designed as a cross-sectional case series and quasi-case-control study. Patients with a diagnosis of methanol poisoning on admission to hospitals were identified for the study. Diagnosis was established when (i) a history of recent ingestion of illicit spirits was available and serum methanol was higher than 6.2 mmol/L (20 mg/dL), or (ii) there was a history/clinical suspicion of methanol poisoning, and serum methanol was above the limit of detection with at least two of the following: pH < 7.3, serum bicarbonate < 20 mmol/L, and anion gap or AG ≥ 20 mmol/L. Fomepizole was given as a bolus dose of 15 mg/kg i.v. diluted in isotonic saline, followed by 10 mg/kg every 12 h (every 4 h during hemodialysis); ethanol was administered both intravenously as a 10% solution in 5% glucose, and per os in boluses of 20% solution. Multivariate regression was applied to determine the effect of antidote on outcome. Additionally, for a retrospective quasi-case-control study, a control group of patients treated with ethanol, matched carefully on severity of poisoning and other key parameters, was selected. RESULTS: Data were obtained from 100 hospitalized patients with confirmed poisoning: 25 patients treated with fomepizole were compared with 68 patients receiving ethanol (seven patients did not receive any antidote). More severely acidotic (p < 0.001) and late-presenting (>12 h; p = 0.028) patients received fomepizole more often than ethanol, as reflected in the higher number of fomepizole-treated patients being intubated (p = 0.009). No association was found between the type of antidote and the survival in either the case series (p = 0.205) or the quasi-control groups (p = 0.705) in which patients were very closely matched to minimize confounding by allocation. In the multivariate analysis, positive serum ethanol (odds ratio [OR], 10.8; 95% confidence interval [CI], 2.9-39.9) and arterial blood pH (OR, 3.7; 95% CI, 1.3-10.5) on admission were the only independent variables for the survival. The median intensive care unit length of stay was 6 (range, 2-22) days in the fomepizole group and 4 (range, 1-33) days in the ethanol group (p = 0.131). There were no differences in the use of elimination techniques between the two groups (neither in the full material (n = 100), nor the case-control groups (n = 50)). CONCLUSIONS: This study on antidotes for methanol poisoning did not show any evidence of different clinical effectiveness. Although ethanol is generally associated with a higher incidence of complications, this study suggests that both antidotes are similarly effective and that ethanol should not be avoided on grounds of effectiveness.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000106
- 003
- CZ-PrNML
- 005
- 20160122125447.0
- 007
- ta
- 008
- 160108s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/15563650.2015.1059946 $2 doi
- 035 __
- $a (PubMed)26109326
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zakharov, Sergey $u Department of Occupational Medicine, Toxicological Information Center, First Faculty of Medicine, Charles University in Prague and General University Hospital , Na Bojisti, Prague , Czech Republic.
- 245 10
- $a Fomepizole versus ethanol in the treatment of acute methanol poisoning: Comparison of clinical effectiveness in a mass poisoning outbreak / $c S. Zakharov, D. Pelclova, T. Navratil, J. Belacek, M. Komarc, M. Eddleston, KE. Hovda,
- 520 9_
- $a CONTEXT: Mass or cluster methanol poisonings are frequently reported from around the world. The comparative effectiveness of ethanol and fomepizole as antidotes for methanol poisoning is unknown due to the difficulty of performing a randomized controlled trial. OBJECTIVE: During an outbreak of mass poisonings in the Czech Republic in 2012-2014, we compared the effects of antidotes on the frequency of health sequelae and mortality. METHODS: The study was designed as a cross-sectional case series and quasi-case-control study. Patients with a diagnosis of methanol poisoning on admission to hospitals were identified for the study. Diagnosis was established when (i) a history of recent ingestion of illicit spirits was available and serum methanol was higher than 6.2 mmol/L (20 mg/dL), or (ii) there was a history/clinical suspicion of methanol poisoning, and serum methanol was above the limit of detection with at least two of the following: pH < 7.3, serum bicarbonate < 20 mmol/L, and anion gap or AG ≥ 20 mmol/L. Fomepizole was given as a bolus dose of 15 mg/kg i.v. diluted in isotonic saline, followed by 10 mg/kg every 12 h (every 4 h during hemodialysis); ethanol was administered both intravenously as a 10% solution in 5% glucose, and per os in boluses of 20% solution. Multivariate regression was applied to determine the effect of antidote on outcome. Additionally, for a retrospective quasi-case-control study, a control group of patients treated with ethanol, matched carefully on severity of poisoning and other key parameters, was selected. RESULTS: Data were obtained from 100 hospitalized patients with confirmed poisoning: 25 patients treated with fomepizole were compared with 68 patients receiving ethanol (seven patients did not receive any antidote). More severely acidotic (p < 0.001) and late-presenting (>12 h; p = 0.028) patients received fomepizole more often than ethanol, as reflected in the higher number of fomepizole-treated patients being intubated (p = 0.009). No association was found between the type of antidote and the survival in either the case series (p = 0.205) or the quasi-control groups (p = 0.705) in which patients were very closely matched to minimize confounding by allocation. In the multivariate analysis, positive serum ethanol (odds ratio [OR], 10.8; 95% confidence interval [CI], 2.9-39.9) and arterial blood pH (OR, 3.7; 95% CI, 1.3-10.5) on admission were the only independent variables for the survival. The median intensive care unit length of stay was 6 (range, 2-22) days in the fomepizole group and 4 (range, 1-33) days in the ethanol group (p = 0.131). There were no differences in the use of elimination techniques between the two groups (neither in the full material (n = 100), nor the case-control groups (n = 50)). CONCLUSIONS: This study on antidotes for methanol poisoning did not show any evidence of different clinical effectiveness. Although ethanol is generally associated with a higher incidence of complications, this study suggests that both antidotes are similarly effective and that ethanol should not be avoided on grounds of effectiveness.
- 650 _2
- $a intravenózní podání $7 D061605
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antidota $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000931
- 650 _2
- $a rozdělení chí kvadrát $7 D016009
- 650 _2
- $a průřezové studie $7 D003430
- 650 12
- $a epidemický výskyt choroby $7 D004196
- 650 _2
- $a rozvrh dávkování léků $7 D004334
- 650 _2
- $a ethanol $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000431
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a hospitalizace $7 D006760
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jednotky intenzivní péče $7 D007362
- 650 _2
- $a délka pobytu $7 D007902
- 650 _2
- $a lineární modely $7 D016014
- 650 _2
- $a logistické modely $7 D016015
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methanol $x otrava $7 D000432
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a otrava $x diagnóza $x farmakoterapie $x mortalita $7 D011041
- 650 _2
- $a pyrazoly $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011720
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a mladý dospělý $7 D055815
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pelclova, Daniela
- 700 1_
- $a Navratil, Tomas
- 700 1_
- $a Belacek, Jaromir
- 700 1_
- $a Komarc, Martin
- 700 1_
- $a Eddleston, Michael
- 700 1_
- $a Hovda, Knut Erik
- 773 0_
- $w MED00013938 $t Clinical toxicology (Philadelphia, Pa.) $x 1556-9519 $g Roč. 53, č. 8 (2015), s. 797-806
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26109326 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20160122125607 $b ABA008
- 999 __
- $a ok $b bmc $g 1102387 $s 924312
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 53 $c 8 $d 797-806 $e 20150624 $i 1556-9519 $m Clinical toxicology $n Clin Toxicol (Phila) $x MED00013938
- LZP __
- $a Pubmed-20160108